Simergent closed a $1.2M seed round on October 17, 2017, with i2E's Oklahoma Seed Capital Fund as the lead investor. We are grateful to i2E and all our high quality investors. Nephrologists around the globe are excited about the prospect of our Archimedes dialysis device, which provides significant cost reduction for home dialysis while the patient sleeps, thus allowing patients to live a normal life rather than traveling to a dialysis clinic 3 days per week. This funding will provide the necessary resources for Simergent to expand our team of engineers, enhance the device’s design, and perform patient-centered activities required for regulatory approvals.

Read the full press release here.